All Updates

All Updates

icon
Filter
Partnerships
Coya Therapeutics expands research collaboration with Houston Methodist Research Institute to advance regulatory T-cell exosome platform
Precision Medicine
Jun 20, 2024
Last week:
Product updates
Eve Air Mobility unveils unmanned eVTOL prototype
Passenger eVTOL Aircraft
Yesterday
Product updates
Lilium advances POWER-ON, providing solutions with leading digital innovators
Passenger eVTOL Aircraft
Yesterday
Industry news
New South Korean space agency provides rundown of plans
Space Travel and Exploration Tech
Jul 20, 2024
Management news
Bionano Genomics receives Nasdaq non-compliance notice; continues trading efforts
Precision Medicine
Jul 19, 2024
Funding
GRO Biosciences raises USD 60.3 million in Series B funding to advance lead program into clinical trials and expand GRObio pipeline
Precision Medicine
Jul 19, 2024
Management news
Yooz announces new appointments in C-Suite
Business Expense Management
Jul 19, 2024
Regulation/policy
Airwallex secures license to expand retail investment offerings in Australia
FinTech Infrastructure
Jul 19, 2024
Partnerships
EHang collaborates with KC Smart Mobility to expand EH216-S sales and operations in China
Passenger eVTOL Aircraft
Jul 19, 2024
Industry news
China launches Gaofen-11 high-resolution intelligence satellite
Satellite Management
Jul 19, 2024
Industry news
France funds miniature satellite capture and inspection mission
Satellite Management
Jul 19, 2024
Precision Medicine

Precision Medicine

Jun 20, 2024

Coya Therapeutics expands research collaboration with Houston Methodist Research Institute to advance regulatory T-cell exosome platform

Partnerships

  • Coya Therapeutics collaborates with the Houston Methodist Research Institute (HMRI) to expand its existing research relationship. The research focuses on enhancing the functions of regulatory T cells (Tregs) to target severe neurodegenerative and autoimmune diseases. The Johnson Center for Cellular Therapeutics funds the research.

  • The research collaboration focuses on developing exosomes from patients' Tregs and analyzing and validating clinical biomarkers to track and manage diseases like amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson's. The agreement aims to combine COYA 301 (LD IL-2) with other relevant drug products to develop a unique approach to addressing the multifaceted pathophysiology of ailments and to form new strategies for future collaborations. 

  • Coya Therapeutics is a clinical-stage biotechnology company focused on developing treatments based on regulatory T cells (Tregs), targeting neurodegenerative, autoimmune, and metabolic diseases. The company's pipeline includes multiple Tregs-based programs, including its lead candidate, COYA 302, which combines COYA 301 (a low-dose IL-2) with CTLA4-Ig to enhance Treg function and reduce pro-inflammatory mediators, targeting conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, and Alzheimer's disease​.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.